miRagen Therapeutics Release: Therapeutic Dosing of Synthetic AntimiR Further Demonstrates the Potential of microRNA-208 Inhibition in Treatment of Chronic Heart Failure

Published: Sep 07, 2011

BOULDER, Colo.--(BUSINESS WIRE)--miRagen Therapeutics, Inc., a preclinical-stage biopharmaceutical company focused on improving patients’ lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, announced that new preclinical data published in today’s online edition of Circulation suggest that therapeutic inhibition of microRNA-208 (miR-208) may improve cardiac function and survival rates during heart failure.

Back to news